Articles On Telix Pharmaceuticals (ASX:TLX)

Highlights Former L’Oreal MD to lead Live Verdure’s (ASX:LV1) ‘8 Seeds’ Skincare Dexus (ASX:DXS) shares FY21 results, NPAT up 17% Westpac’s (ASX:WBC) CET1 ratio in 3Q21 lowers, Bank mulls on capital return  The S&P/ASX200 is...

Highlights AVITA Medical disclosed that the US Food and Drug Administration (FDA) has authorised its request to amend the RECELL® System pivotal trial. Pharmaxis has granted Aptar Pharma an exclusive 12-month option for developing and...

Paul Hopper has been behind a number of successful oncology biotechs, and his latest venture is one of the few Australian companies in the radio-pharmaceuticals space. Hopper is best known for being behind Viraltyics which was bought by Mer...

Global markets stay cool US stocks edged higher overnight to post their fifth straight day of gains, as attention centred around geo-political concerns following the US withdrawal from Afghanistan. The Dow Jones rose by 0.31%, and the S&am...

Telix Pharmaceuticals (ASX:TLX) has announced that it has received authorisation to decommission the first of two cyclotrons housed at its licensed radiopharmaceutical production facility in Belgium and updated on a new clinical tri...

The big end of town cooled off a bit to end the week, as mining stocks eased back while the broader ASX200 drifted lower into the close. It followed two days of strong gains for the ASX200 Materials index, which gained an impressive 7.3% fo...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a subdued note. At the time of writing, the benchmark index is down 0.1% to 7,408.1 points. Four ASX shares that are not letting that hold them back a...

Most ASX large cap sectors finished in the red today, in a topsy-turvy session which saw the ASX200 fall sharply at the open then claw back ground, before losing steam into the close of trade. Yesterday’s rotation out of large cap mining &a...

The ASX Healthcare index rose by 0.45% this morning, compared with the broader index which fell by 0.80%, helped by medicinal cannabis company AusCann (ASX:AC8). It rose by 5% in morning trading. AusCann announced it has submitted the first...

Healthcare is a constantly changing industry in which you may be asking yourself if your investments are up to date. While the healthcare sector underperformed the S&P/ASX 200 Index (ASX: XJO) in FY21, there were still some ASX-listed...

Gains for the technology sector spurred a 2.3% rise for the ASX200 in June, the eleventh month of gains for a financial year that returned 27.8%. -The ASX200 climbed 2.3% during June and the FY21 total return was 27.8%-In June Technology wa...

As we’ve covered extensively on the Fool over the past week, the S&P/ASX 200 Index (ASX: XJO) had a very successful year over the last financial year that has just passed us by. Over FY2021, the ASX 200 managed to add a very healthy 24...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Summary  The benchmark index, ASX 200,  had a decent run in June, with a ~2.4% growth.     Several ASX-listed players had a strong June 2021 driven by key developments and are poised to progress further.  Sayona Mining, Liontown,...

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

In late morning trade, the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a positive note. At the time of writing, the benchmark index is up 0.25% to 7,294.5 points. Four ASX shares climbing more than most today are li...

Telix Pharmaceuticals (ASX:TLX) says a first patient has been dosed in a phase one study of TLX250-CDx ( 89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley Hospital in Perth.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been among the worst performers on the All Ordinaries on Monday. The biopharmaceutical company’s shares were down as much as 14% to $5.53 at one stage. Despite this, the Telix share...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and trading lower. At the time of writing, the benchmark index is down 0.3% to 7,363.5 points. Four ASX shares that are not letting that hold them back are liste...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is edging lower on Thursday morning despite the release of a positive announcement. At the time of writing, the biopharmaceuticals company’s shares are down slightly to $5.61. What did T...

Summary Neuroprotective drug developer Argenica Therapeutics commenced trading on the ASX after a well-supported AU$7 million capital raising. The Company disclosed that the ASX listing would allow it to develop its novel neuroprotecti...

One area of the share market that is home to a number of quality options for investors is the mid cap space. But which ones should you consider buying? Two to get better acquainted with are listed below: Hipages Group Holdings Ltd (ASX: H...

Tech stocks push Wall Street near all-time highs All major US indices rose on Friday to close near their all-time highs, with tech stocks being the main driver. The Dow Jones rose by 0.52%, just 0.1% shy of its all-time high. S&P 500 cl...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is having a negative day despite announcing an exciting co-promotion agreement. At the time of writing, the biotechnology company’s shares are fetching for $4.35, down 2.25%. Telix expand...

The diagnostics imaging industry has come a long way since the days of X-rays and CT scans – two technologies that have been around for decades. Although they have not been replaced entirely, a breed of new ASX small caps have emerged over...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is rocketing higher, nearing on its all-time high of $4.80. This follows the biotechnology company’s update on its bone marrow conditioning investigational candidate, TLX66. At the time...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. At the time of writing, the benchmark index is up 0.5% to 7,082.4 points. Four ASX shares that are climbing more than most...

Telix Pharmaceuticals (ASX:TLX) has announced that its bone marrow conditioning investigational candidate TLX66 has met the objectives of a phase I/IIa trial in demonstrating the initial safety profile in patients with AL amyloidosi...

Summary Oncology firm Telix Pharmaceuticals has entered into an exclusive commercial distribution agreement to distribute its product in the German market. Proteomics has secured a significant contract for pharmacokinetic testing, whil...

Summary Telix Pharmaceuticals signs distribution agreement with Germany based company Proteomics International bags new pharmacokinetic testing contract com accomplishes A$428 million institutional entitlement offer Citi hikes PT for...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the move today. This follows the biotechnology company’s announcement that it has inked a new lucrative deal. At the time of writing, the Telix Pharmaceuticals share price is tradi...

Telix (ASX:TLX) has announced an exclusive commercial distribution agreement with Eckert & Ziegler for its prostate cancer imaging product Illuccix for the German market.

Telix Pharmaceuticals (ASX:TLX) says it has been granted HREC approval and received CTN clearance by the TGA for a phase 3 clinical trial of its PSMA targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab).

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s b...

Summary Oncology player Telix Pharmaceuticals has commenced Phase 3 clinical trial of its prostate cancer therapy candidate. Polymer implants manufacturer Osteopore Limited has obtained CE certification for a significantly broader rang...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price will be in focus today after the company announced its prostate cancer therapy has been approved for stage III clinical trials. Shares in the company closed last session trading at $3.94...

Telix Pharmaceuticals (ASX:TLX) has announced an agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

Wall Street bounces back All major indices in the US have bounced back, after falling the previous day. Both the Dow Jones and S&P 500 rose by 0.93%, while tech heavy NASDAQ also rose by 1.19%. It was a broad-based increase across all s...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has the wobbles today after the company shared news of a successful trial.   The biopharmaceutical company announced that its kidney cancer imaging product’s Japanese clinical study met...

Global equities tumble All major world indices tumbled overnight as COVID-19 deaths spiked in India and elsewhere. In the US, the Dow Jones dropped 0.75%, S&P500 shed 0.68%, while tech heavy NASDAQ also tumbled by 0.92%. Europe recorded...

19 Apr 2021 - Telix Pharmaceuticals (ASX:TLX) has announced the launch of the "Nobody Left Behind" ("NOBLE") Registry.

Source: Have a nice day Photo, Shutterstock Summary Telix Pharmaceuticals has announced the launch of NOBLE Registry of its prostate cancer imaging agent. Global healthcare company Ramsay Health Care confirms the funding guarantee arr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With stock...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is storming higher this morning. At the time of writing, the clinical-stage biopharmaceutical company’s shares are up 5% to $4.24. Why is the Telix share price rising? Investors have bee...

Telix Pharmaceuticals (ASX:TLX) has announced an agreement with contract development and manufacturing organisation Grand River Aseptic Manufacturing (‘GRAM’) to perform commercial-scale manufacturing of its Illuccix product.

31 Mar 2021 - Telix Pharmaceuticals (ASX:TLX) has completed an agreement with contract development and manufacturing organisation Grand River Aseptic Manufacturing to perform comme…

Michael Gable is an expert guest commentator for the Finance News Network, presenting “Stock Watch” each week – covering stock tips and shares on the Australian market (ASX). This video is dated 22 March 2021.  Shares covered: NASDAQ, (ASX:...

Source: Enjoy The Life, Shutterstock Summary ASX 200 increased 0.8% on Friday, however it edged lower Monday morning with a decline of almost 33% following the quarterly rebalance announcement. ASX 200 saw 6 new companies being added...